Key result
A 54-year-old woman developed anti-HMGCR myopathy after 5 years of uncomplicated atorvastatin use, presenting with proximal muscle weakness and elevated creatine kinase that resolved with oral prednisone.
Why the study?
Anti-HMGCR myopathy is a rare, serious statin-induced necrotizing myositis causing persistent muscle weakness, highlighting the need for clinicians to recognize this late-onset complication even after years of uncomplicated statin use.
Case Report (n=1)
No
Anti-HMGCR myopathy is a rare but serious complication of statin therapy that can present years after initiation and requires immunosuppressive treatment such as steroids.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to anti-HMGCR myositis in statin users; hypothesis-generating and leaves open prevalence plus management strategies.
N. Irvine (2020) conducted a case report in Anti-HMGCR Myopathy (n=1). Atorvastatin was evaluated on Serum creatine kinase (CK) normalization and alleviation of muscle weakness. A 54-year-old woman developed anti-HMGCR myopathy after 5 years of uncomplicated atorvastatin use, presenting with proximal muscle weakness and elevated creatine kinase that resolved with oral prednisone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: